Latest Blog Posts Tagged "Research News"
April 16, 2014
Some new projects in the MJFF-funded portfolio focus on learning more about the protein parkin and targeting it with therapies to slow or stop Parkinson's.
April 14, 2014
Researchers have reported on a potential route through which mutations in the LRRK2 gene — the greatest known genetic contributor to Parkinson's disease (PD) — lead to cell death.
April 09, 2014
Proteins in baker's yeast may serve a similar purpose as a protein linked with Parkinson's disease.
April 04, 2014
WHAM in Rochester, New York ran a piece on the Phase III study of isradipine happening at the University of Rochester. MJFF funded Phase II.
April 04, 2014
A recent paper reported that coenzyme Q10, an antioxidant previously showed to slow Parkinson's progression, had no clinical benefit for people with PD.
April 03, 2014
The GPS in smartphones may allow researchers to monitor Parkinson's progression through measure of a patient's Lifespace: the geographical area in which one lives and conducts activities.
April 02, 2014
Scott Hadly tells of the latest research from 23andMe's Parkinson's Research Community finding differences in symptom severity in various groups.
Podcast: Drug That May Slow Parkinson's Progression Granted $23 Million from NIH for Phase III Testing
March 31, 2014
Tanya Simuni, MD, principal investigator of the STEADY-PD, and MJFF CEO Todd Sherer talk about the study of isradipine, recently granted $23 million from the NIH for Phase III testing.
March 24, 2014
A recent paper in The Journal of the American Medical Association found that the top reason clinical trials were discontinued was poor participant recruitment.
March 17, 2014
Recently published findings from an MJFF-supported project report that Parkinson's patients with higher levels of the protein alpha-synuclein in spinal fluid experienced faster cognitive decline.